Gene Therapy. Catecholaminergic polymorphic ventricular tachycardia is a hereditary disease that can cause ventricular tachyarrhythmias, and may be fatal in up to 50% of patients by 20 years of age. Its cause is well known to be due to abnormalities in two proteins in the cardiomyocytes that regulate calcium metabolism. A study has now been published in Circulation (2014; 129,2673-2681), evaluating the possibility of modifying the abnormal proteins by gene therapy in rodents. However, as the authors state, extensive studies will still be required before its use in human medicine.
La entrada Gene therapy applied to ventricular tachyarrhythmias aparece primero en Observatorio de Bioética, UCV.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.